Things appear to be on track now with the trial after a few setbacks -
"Antisense has continued to make good progress with the deployment of an ongoing international phase IIb clinical trial of ATL1102 in Duchenne muscular dystrophy (DMD). As of 31 October 2023, all four participating countries are open to recruitment. To date, 10 patients have been randomised and are receiving study medication, with a number of additional patients currently in screening.
The independent Data Safety Monitoring Board (DSMB) has met to review emerging safety data from the study and has not at this stage identified any concerns that may require alterations to the conduct of the study. The DSMB will continue to meet at regular intervals throughout the course of the study to ensure that any emergent safety considerations are rapidly evaluated.
To date, no randomised patient has withdrawn from the study, and feedback from participating investigators has been that there is a high level of interest in the study from patients and families. Self-administration of study medication, which can be a potential concern with investigational drugs such as ATL1102, has been entirely unproblematic thus far."
GLTAH's
.
ANP Price at posting:
5.9¢ Sentiment: Hold Disclosure: Held
